CompletedNCT06654817
Efficacy and Safety Evaluation of Anti-CD20 Monoclonal Antibody Combined with Azathioprine and Corticosteroids in the Treatment of Pemphigus Vulgaris
Studying Pemphigus vulgaris
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Chao Ji
- Principal Investigator
- Zhuang Zheyu Zheyu Zhuang, BCBAChao Ji
- Intervention
- Ofatumumab subcutaneous injection(drug)
- Enrollment
- 38 target
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2023 – 2024
Study locations (1)
- First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06654817 on ClinicalTrials.govOther trials for Pemphigus vulgaris
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07384221Periodontal Status and Disease Severity in Pemphigus Vulgaris PatientsSaglik Bilimleri Universitesi
- RECRUITINGPHASE1, PHASE2NCT04422912A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)Cabaletta Bio
- RECRUITINGNCT02753777Autoimmune Blistering Diseases StudyUniversity of Pennsylvania